Income Statement Processa Pharmaceuticals, Inc.

Stocks

PCSA

US74275C4033

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-09 EDT			5-day change	1st Jan Change
1.520 ^USD	+12.59%		-5.59%	-47.22%

08-14	Processa Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-29	Processa Pharmaceuticals, Inc. announced that it has received $200 million in funding from a group of investors	CI

55fba1a5.h7ARnxobSQBSRQDJ7oITbEEdDb3tWHHs2otC1daBdYQ.9tI823E2J2RjdGiRhrpDNgl1eOiXDCWYvL0ok6K2Q-PP2Hz6TG8KS2p2Yw

Published financial data: PROCESSA PHARMACEUTICALS, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Selling General & Admin Expenses, Total	4.69M	8.76M	5.66M	4.78M	6.18M
R&D Expenses	6.88M	11.49M	5.8M	7.27M	7.81M
Other Operating Expenses, Total	11.57M	20.26M	11.46M	12.05M	13.99M
Operating Income	-11.57M	-20.26M	-11.46M	-12.05M	-13.99M
Interest Expense, Total	-362	-	-	-	-
Interest And Investment Income	11.99K	101K	336K	201K	109K
Net Interest Expenses	11.63K	101K	336K	201K	109K
Other Non Operating Income (Expenses)	-	-	-	-	315K
EBT, Excl. Unusual Items	-11.56M	-20.16M	-11.12M	-11.85M	-13.56M
Merger & Related Restructuring Charges	-	-	-	-	-
Asset Writedown	-	-7.27M	-	-	-
In Process R&D Expenses	-567K	-	-	-	-
Other Unusual Items	164K	-	-	-	-
EBT, Incl. Unusual Items	-11.96M	-27.42M	-11.12M	-11.85M	-13.56M
Income Tax Expense	-531K	-	-	-	-
Earnings From Continuing Operations	-11.43M	-27.42M	-11.12M	-11.85M	-13.56M
Net Income to Company	-11.43M	-27.42M	-11.12M	-11.85M	-13.56M
Net Income - (IS)	-11.43M	-27.42M	-11.12M	-11.85M	-13.56M
Preferred Dividend and Other Adjustments	-	-	-	-	-
Net Income to Common Incl Extra Items	-11.43M	-27.42M	-11.12M	-11.85M	-13.56M
Net Income to Common Excl. Extra Items	-11.43M	-27.42M	-11.12M	-11.85M	-13.56M
Per Share Items
Net EPS - Basic	-372.97	-851.18	-211.99	-96.82	-10.36
Basic EPS - Continuing Operations	-372.97	-851.18	-211.99	-96.82	-10.36
Basic Weighted Average Shares Outstanding	30.64K	32.22K	52.46K	122K	1.31M
Net EPS - Diluted	-372.97	-851.18	-211.99	-96.82	-10.36
Diluted EPS - Continuing Operations	-372.97	-851.18	-211.99	-96.82	-10.36
Diluted Weighted Average Shares Outstanding	30.64K	32.22K	52.46K	122K	1.31M
Normalized Basic EPS	-235.72	-391	-132.49	-60.51	-6.47
Normalized Diluted EPS	-235.72	-391	-132.49	-60.51	-6.47
Supplemental Items
EBITDA	-10.78M	-19.47M	-11.46M	-12.05M	-13.99M
EBITA	-10.78M	-19.47M	-11.46M	-12.05M	-13.99M
EBIT	-11.57M	-20.26M	-11.46M	-12.05M	-13.99M
EBITDAR	-10.68M	-19.37M	-11.36M	-11.96M	-
Effective Tax Rate - (Ratio)	4.44	-	-	-	-
Deferred Domestic Taxes	-531K	0	0	-	-
Total Deferred Taxes	-531K	0	0	-	-
Normalized Net Income	-7.22M	-12.6M	-6.95M	-7.41M	-8.48M
Interest on Long-Term Debt	362	-	-	-	-
Supplemental Operating Expense Items
Advertising Expense	-	-	-	-	-
Marketing Expenses	-	-	-	-	-
General and Administrative Expenses	4.59M	8.76M	5.66M	4.78M	6.18M
Research And Development Expense From Footnotes	7.44M	11.49M	5.8M	7.27M	7.81M
Net Rental Expense, Total	94.26K	96.78K	97K	90K	-
Imputed Operating Lease Interest Expense	1.34K	-	-	-	-
Imputed Operating Lease Depreciation	92.92K	-	-	-	-
Stock-Based Comp., R&D Exp. (Total)	810K	2.9M	364K	169K	193K
Stock-Based Comp., G&A Exp. (Total)	2.6M	5.93M	2.01M	460K	665K
Total Stock-Based Compensation	3.41M	8.83M	2.37M	630K	858K

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Assets
Cash And Equivalents	16.5M	6.5M	4.71M	1.19M	5.54M
Short Term Investments	-	-	-	-	-
Total Cash And Short Term Investments	16.5M	6.5M	4.71M	1.19M	5.54M
Other Receivables	70.27K	-	-	-	-
Total Receivables	70.27K	-	-	-	-
Prepaid Expenses	1.76M	1.88M	926K	682K	134K
Other Current Assets, Total	-	-	-	-	-
Total Current Assets	18.33M	8.39M	5.63M	1.87M	5.67M
Gross Property Plant And Equipment	83.51K	-	-	-	-
Accumulated Depreciation	-9.33K	-	-	-	-
Net Property Plant And Equipment	74.18K	228K	149K	75.69K	3.81K
Other Intangibles, Total	8.06M	0	-	-	-
Other Long-Term Assets, Total	5.54K	5.54K	5.54K	1.28M	2.14M
Total Assets	26.46M	8.62M	5.79M	3.23M	7.81M
Liabilities
Accounts Payable, Total	219K	328K	312K	881K	1.06M
Accrued Expenses, Total	279K	403K	146K	579K	1.18M
Short-term Borrowings	-	-	-	-	-
Current Portion of Long-Term Debt	-	-	-	-	-
Current Portion of Leases	71.08K	78.9K	83.65K	73.02K	-
Other Current Liabilities	402K	189K	189K	-	-
Total Current Liabilities	971K	999K	731K	1.53M	2.24M
Long-Term Debt	-	-	-	-	-
Long-Term Leases	7.38K	151K	66.9K	487	-
Deferred Tax Liability Non Current	-	-	-	-	-
Other Non Current Liabilities	-	-	-	-	-
Total Liabilities	978K	1.15M	797K	1.53M	2.24M
Common Stock, Total	1.57K	1.61K	129	371	257
Additional Paid In Capital	62.31M	72.02M	80.66M	89.21M	107M
Retained Earnings	-36.82M	-64.25M	-75.37M	-87.22M	-101M
Treasury Stock	-	-300K	-300K	-300K	-300K
Comprehensive Income and Other	-	-	-	-	-
Total Common Equity	25.49M	7.47M	4.99M	1.7M	5.58M
Total Equity	25.49M	7.47M	4.99M	1.7M	5.58M
Total Liabilities And Equity	26.46M	8.62M	5.79M	3.23M	7.81M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	31.69K	49.12K	114K	211K	2.66M
ECS Total Common Shares Outstanding	31.42K	32.07K	51.44K	148K	2.57M
Book Value / Share	811.11	232.94	96.99	11.45	2.17
Tangible Book Value	17.43M	7.47M	4.99M	1.7M	5.58M
Tangible Book Value Per Share	554.69	232.94	96.99	11.45	2.17
Total Debt	78.46K	229K	151K	73.51K	0
Net Debt	-16.42M	-6.27M	-4.56M	-1.12M	-5.54M
Debt Equivalent Oper. Leases	754K	774K	776K	720K	-
Account Code - Inventory Valuation	3	3	3	3	3
Machinery, Total	9.33K	-	-	-	-
Full Time Employees	15	15	13	10	12

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Net Income	-11.43M	-27.42M	-11.12M	-11.85M	-13.56M
Depreciation & Amortization - CF	484	-	222	782	1.2K
Amortization of Goodwill and Intangible Assets - (CF)	790K	788K	-	-	-
Depreciation & Amortization, Total	791K	788K	222	782	1.2K
Amortization of Deferred Charges, Total - (CF)	-	116K	-	-	-
Asset Writedown & Restructuring Costs	300K	7.27M	-	-	-
Stock-Based Compensation (CF)	3.41M	8.83M	1.06M	630K	858K
Other Operating Activities, Total	-610K	275K	1.39M	87.18K	-225K
Change In Accounts Receivable	6.75K	70.27K	-	-	-
Change In Accounts Payable	-102K	109K	-15.93K	569K	176K
Change in Other Net Operating Assets	-1.08M	365K	621K	-682K	1.37M
Cash from Operations	-8.72M	-9.61M	-8.06M	-11.25M	-11.39M
Capital Expenditure	-	-	-2.78K	-3.24K	-
Cash Acquisitions	-	-	-	-	-
Sale (Purchase) of Intangible assets	-	-	-	-	-
Investment in Marketable and Equity Securities, Total	-	-	-	-	-
Other Investing Activities, Total	-	-	-	-	-850K
Cash from Investing	-	-	-2.78K	-3.24K	-850K
Short Term Debt Issued, Total	-	-	-	-	-
Long-Term Debt Issued, Total	-	-	-	-	-
Total Debt Issued	-	-	-	-	-
Long-Term Debt Repaid, Total	-	-	-	-5.2K	-6.6K
Total Debt Repaid	-	-	-	-5.2K	-6.6K
Issuance of Common Stock	10.05M	-	6.32M	7.76M	16.6M
Repurchase of Common Stock	-64.4K	-389K	-52.75K	-24.46K	-10.4K
Other Financing Activities, Total	-186K	-	-	-	-
Cash from Financing	9.8M	-389K	6.27M	7.73M	16.58M
Net Change in Cash	1.08M	-9.99M	-1.8M	-3.51M	4.35M
Supplemental Items
Cash Interest Paid	-	-	-	1.2K	5.61K
Levered Free Cash Flow	-4.19M	-2.96M	-4.11M	-5.85M	-6.55M
Unlevered Free Cash Flow	-4.19M	-3.08M	-4.11M	-5.85M	-6.55M
Change In Net Working Capital	1.16M	33.85K	-684K	-1.06M	-1.33M
Net Debt Issued / Repaid	-	-	-	-5.2K	-6.6K

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Profitability
Return on Assets	-27.98	-72.18	-99.41	-167.08	-158.34
Return on Total Capital	-29.61	-76.12	-111.54	-218.02	-238
Return On Equity %	-47.2	-166.43	-178.52	-354.51	-372.97
Return on Common Equity	-47.2	-166.43	-178.52	-354.51	-372.97
Short Term Liquidity
Current Ratio	18.87	8.4	7.71	1.22	2.54
Quick Ratio	17.06	6.51	6.44	0.78	2.48
Operating Cash Flow to Current Liabilities	-8.98	-9.62	-11.04	-7.34	-5.09
Long Term Solvency
Total Debt/Equity	0.31	3.07	3.02	4.33	-
Total Debt / Total Capital	0.31	2.98	2.93	4.15	-
LT Debt/Equity	0.03	2.02	1.34	0.03	-
Long-Term Debt / Total Capital	0.03	1.96	1.3	0.03	-
Total Liabilities / Total Assets	3.7	13.33	13.78	47.48	28.62
EBIT / Interest Expense	-31.95K	-	-	-	-
EBITDA / Interest Expense	-29.51K	-	-	-	-
(EBITDA - Capex) / Interest Expense	-29.51K	-	-	-	-
Total Debt / EBITDA	-0.01	-0.01	-0.01	-0.01	-
Net Debt / EBITDA	1.54	0.32	0.4	0.09	0.4
Total Debt / (EBITDA - Capex)	-0.01	-0.01	-0.01	-0.01	-
Net Debt / (EBITDA - Capex)	1.54	0.32	0.4	0.09	0.4
Growth Over Prior Year
EBITDA, 1 Yr. Growth %	91.3	80.67	-41.15	5.18	16.07
EBITA, 1 Yr. Growth %	91.02	80.66	-41.15	5.19	16.08
EBIT, 1 Yr. Growth %	79.7	75.13	-43.44	5.19	16.08
Earnings From Cont. Operations, 1 Yr. Growth %	-20.72	139.98	-59.45	6.55	14.46
Net Income, 1 Yr. Growth %	-20.72	139.98	-59.45	6.55	14.46
Normalized Net Income, 1 Yr. Growth %	72.09	74.43	-44.82	6.55	14.46
Diluted EPS Before Extra, 1 Yr. Growth %	-70.62	128.22	-75.09	-54.33	-89.3
Net Property, Plant and Equip., 1 Yr. Growth %	-53.36	206.8	-34.7	-49.07	-94.96
Total Assets, 1 Yr. Growth %	4.95	-67.43	-32.87	-44.19	141.96
Tangible Book Value, 1 Yr. Growth %	23.67	-57.13	-33.22	-66	228.82
Common Equity, 1 Yr. Growth %	11.1	-70.69	-33.22	-66	228.82
Cash From Operations, 1 Yr. Growth %	177.34	10.18	-16.05	39.46	1.25
Capital Expenditures, 1 Yr. Growth %	-	-	-	16.86	-
Levered Free Cash Flow, 1 Yr. Growth %	1.72K	-29.31	38.69	42.37	11.95
Unlevered Free Cash Flow, 1 Yr. Growth %	1.54K	-26.55	33.48	42.37	11.95
Compound Annual Growth Rate Over Two Years
EBITDA, 2 Yr. CAGR %	85.5	85.91	3.11	-21.33	10.49
EBITA, 2 Yr. CAGR %	85.25	85.77	3.11	-21.32	10.5
EBIT, 2 Yr. CAGR %	71.44	77.4	-0.48	-22.87	10.5
Earnings From Cont. Operations, 2 Yr. CAGR %	84.48	37.94	-1.35	-34.27	10.44
Net Income, 2 Yr. CAGR %	84.48	37.94	-1.35	-34.27	10.44
Normalized Net Income, 2 Yr. CAGR %	70.81	73.26	-1.9	-23.32	10.44
Diluted EPS Before Extra, 2 Yr. CAGR %	3.27	-18.11	-24.61	-66.27	-77.89
Net Property, Plant and Equip., 2 Yr. CAGR %	-42.96	19.62	41.54	-42.33	-83.98
Total Assets, 2 Yr. CAGR %	55.94	-41.53	-53.24	-38.79	16.2
Tangible Book Value, 2 Yr. CAGR %	227	-27.19	-46.5	-52.35	5.73
Common Equity, 2 Yr. CAGR %	78.34	-42.93	-55.75	-52.35	5.73
Cash From Operations, 2 Yr. CAGR %	78.04	74.81	-3.82	8.2	18.83
Levered Free Cash Flow, 2 Yr. CAGR %	79.02	258.25	-0.98	40.52	26.31
Unlevered Free Cash Flow, 2 Yr. CAGR %	80.48	247.42	-0.98	37.85	26.31
Compound Annual Growth Rate Over Three Years
EBITDA, 3 Yr. CAGR %	42.1	83.87	26.7	3.8	-10.44
EBITA, 3 Yr. CAGR %	41.99	83.71	26.64	3.8	-10.43
EBIT, 3 Yr. CAGR %	38.21	72.66	21.19	1.38	-11.61
Earnings From Cont. Operations, 3 Yr. CAGR %	44.79	101.38	-8.28	1.22	-20.92
Net Income, 3 Yr. CAGR %	44.79	101.38	-8.28	1.22	-20.92
Normalized Net Income, 3 Yr. CAGR %	36.7	72.01	18.32	0.84	-12.37
Diluted EPS Before Extra, 3 Yr. CAGR %	1.85	34.52	-44.93	-36.21	-77
Net Property, Plant and Equip., 3 Yr. CAGR %	62.23	-0.06	-2.24	0.67	-74.41
Total Assets, 3 Yr. CAGR %	28.47	-7.48	-38.78	-50.4	-3.22
Tangible Book Value, 3 Yr. CAGR %	187.06	66.11	-29.26	-54	-9.28
Common Equity, 3 Yr. CAGR %	37.98	-2.31	-39.86	-59.47	-9.28
Cash From Operations, 3 Yr. CAGR %	32.97	51.72	36.89	8.86	5.83
Levered Free Cash Flow, 3 Yr. CAGR %	27.94	31.34	161.1	11.76	30.31
Unlevered Free Cash Flow, 3 Yr. CAGR %	28.66	33.75	152.57	11.76	28.66
Compound Annual Growth Rate Over Five Years
EBITDA, 5 Yr. CAGR %	41.2	62.06	24.99	30.93	19.95
EBITA, 5 Yr. CAGR %	41.18	62.02	24.93	30.86	19.92
EBIT, 5 Yr. CAGR %	43.19	63.31	21.2	25.09	16.79
Earnings From Cont. Operations, 5 Yr. CAGR %	42.91	71.35	24.19	28.69	-1.21
Net Income, 5 Yr. CAGR %	42.91	71.35	24.19	28.69	-1.21
Normalized Net Income, 5 Yr. CAGR %	43.23	62.16	19.71	24.51	15.1
Diluted EPS Before Extra, 5 Yr. CAGR %	-	-	-9.7	-22.65	-61.77
Net Property, Plant and Equip., 5 Yr. CAGR %	27.07	54.54	53.61	-19.79	-52.58
Total Assets, 5 Yr. CAGR %	62.09	23.64	-14.25	-21.57	-20.89
Tangible Book Value, 5 Yr. CAGR %	50.37	82.09	46.6	0.8	-16.92
Common Equity, 5 Yr. CAGR %	62.24	82.09	-12.45	-26.69	-24.64
Cash From Operations, 5 Yr. CAGR %	32.25	42.15	16.81	32.53	29.36
Levered Free Cash Flow, 5 Yr. CAGR %	23.52	26.16	15.47	34.94	95.28
Unlevered Free Cash Flow, 5 Yr. CAGR %	23.52	27.5	15.87	35.38	91.42